Graybug Vision - GRAY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 314.59 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.60
▼ -0.02 (-3.21%)

This chart shows the closing price for GRAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Graybug Vision Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRAY

Analyst Price Target is $2.50
▲ +314.59% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Graybug Vision in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 314.59% upside from the last price of $0.60.

This chart shows the closing price for GRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Graybug Vision. This rating has held steady since May 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022Piper SandlerLower TargetNeutral$4.00 ➝ $2.00Low
5/11/2022Cantor FitzgeraldLower Target$4.00 ➝ $2.50Medium
3/31/2022WedbushReiterated RatingNeutral$3.00Low
3/25/2022Cantor FitzgeraldReiterated RatingBuy$4.00Low
3/17/2022Cantor FitzgeraldLower TargetOverweight$6.00 ➝ $4.00High
1/3/2022Wells Fargo & CompanyInitiated CoverageOverweightLow
12/15/2021WedbushReiterated RatingNeutralMedium
5/19/2021Needham & Company LLCReiterated RatingBuy ➝ HoldLow
5/18/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$23.00 ➝ $5.00Low
5/13/2021Cantor FitzgeraldLower TargetOverweight$14.00 ➝ $6.00High
5/13/2021Needham & Company LLCDowngradeBuy ➝ HoldHigh
5/12/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$23.00 ➝ $5.00High
5/12/2021Piper SandlerLower TargetNeutral$10.00 ➝ $4.00High
3/15/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$27.00 ➝ $10.00N/A
3/15/2021WedbushReiterated RatingOutperform ➝ Neutral$41.00 ➝ $8.00N/A
3/9/2021WedbushDowngradeOutperform ➝ Neutral$41.00 ➝ $8.00Medium
3/9/2021SVB LeerinkLower TargetOutperform$45.00 ➝ $23.00High
3/9/2021Piper SandlerDowngradeOverweight ➝ Neutral$27.00 ➝ $10.00High
12/21/2020Cantor FitzgeraldInitiated CoverageOverweight$42.00High
10/20/2020OppenheimerInitiated CoverageOutperform$41.00Low
10/20/2020Robert W. BairdInitiated CoverageOverweight$27.00High
10/20/2020SVB LeerinkInitiated CoverageOutperform$35.00High
10/20/2020WedbushInitiated CoverageOutperform$41.00High
10/20/2020Piper SandlerInitiated CoverageOverweight$27.00High
10/20/2020Needham & Company LLCInitiated CoverageBuy$30.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Graybug Vision logo
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Read More

Today's Range

Now: $0.60
Low: $0.60
High: $0.64

50 Day Range

MA: $0.90
Low: $0.60
High: $1.04

52 Week Range

Now: $0.60
Low: $0.60
High: $2.33

Volume

20,868 shs

Average Volume

74,729 shs

Market Capitalization

$13.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Graybug Vision?

The following Wall Street sell-side analysts have issued research reports on Graybug Vision in the last twelve months: Cantor Fitzgerald, Piper Sandler, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for GRAY.

What is the current price target for Graybug Vision?

3 Wall Street analysts have set twelve-month price targets for Graybug Vision in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 314.6%. Wedbush has the highest price target set, predicting GRAY will reach $3.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $2.00 for Graybug Vision in the next year.
View the latest price targets for GRAY.

What is the current consensus analyst rating for Graybug Vision?

Graybug Vision currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRAY will outperform the market and that investors should add to their positions of Graybug Vision.
View the latest ratings for GRAY.

What other companies compete with Graybug Vision?

How do I contact Graybug Vision's investor relations team?

The company's listed phone number is 650-487-2800 and its investor relations email address is [email protected] The official website for Graybug Vision is www.graybug.com. Learn More about contacing Graybug Vision investor relations.